Pertuzumab and trastuzumab dosing sequence

Pertuzumab (Pertuzumab) and trastuzumab are drugs commonly used to treat HER2-positive breast cancer, and they are often used in combination. Their order can be determined according to the specific situation and the advice of your doctor. Trastuzumab is one of the standard treatments for HER2-positive breast cancer and has been widely used. Patients often receive trastuzumab treatment first.

During trastuzumab treatment, your doctor may decide to add pertuzumab. Intravenous pertuzumab was administered at a loading dose of 840 mg, followed by maintenance doses of 420 mg every 3 weeks, with steady-state concentrations achieved after the first maintenance dose. In its subcutaneous dosage form, pertuzumab has an absolute bioavailability of approximately 0.7 and a mean Tmax of 4 days when combined with hyaluronidase. The subcutaneous dosage form takes advantage of co-delivery with hyaluronidase, which reduces the viscosity of the extracellular matrix (ECM) and enables greater bioavailability for subcutaneous administration. Pertuzumab works together with trastuzumab to more effectively inhibit the growth and spread of cancer cells by inhibiting different regions of the HER2 receptor.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.